Treatment toxicity in endometrial cancer: can we identify and manage it better?

Lancet Oncol. 2018 May;19(5):602. doi: 10.1016/S1470-2045(18)30264-X.

Authors

Matthew S Katz¹, Lesley Smith², Richard Simcock³

Affiliations

¹ Department of Radiation Medicine, Lowell General Hospital, MA, USA. Electronic address: [email protected].
² Pelvic Radiation Disease Association, Epsom, UK; NHS Cancer Programme, NHS England, London, UK.
³ Sussex Cancer Centre, Brighton and Sussex University, East Sussex, UK.

PMID: 29726376
DOI: 10.1016/S1470-2045(18)30264-X

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects*
Chemoradiotherapy, Adjuvant / adverse effects*
Endometrial Neoplasms / diagnosis
Endometrial Neoplasms / mortality
Endometrial Neoplasms / therapy*
Female
Humans
Progression-Free Survival
Quality of Life
Radiotherapy, Adjuvant / adverse effects*
Risk Assessment
Risk Factors
Time Factors

Substances

Antineoplastic Agents